Research explained
Sermorelin vs CJC-1295: Evidence & Differences
Compare sermorelin with long-acting CJC-1295, including DAC terminology, the studied populations and why hormone changes do not establish clinical benefit.
By PurePeptideHub Research Team · Evidence updated
Editorial evidence update; independent clinical review pending. Editorial standards
This comparison concerns the long-acting CJC-1295 studied in the cited trial. Do not transfer its findings to a product labeled no DAC.
Evidence at a glance
Selected sources supporting this update. This is an editorial evidence summary, not a systematic review of every publication.
| Source and design | What it supports | What it cannot establish |
|---|---|---|
| FDA: why GEREF was discontinued 2013 regulatory determination | FDA found that the discontinued GEREF products were not withdrawn for safety or effectiveness reasons. | This historical finding is not approval of a current compounded product or a new indication. |
| Teichman et al., 2006: long-acting CJC-1295 Randomized placebo-controlled studies in healthy adults | The study measured sustained changes in GH and IGF-1 after long-acting CJC-1295. | Hormone measurements are not evidence of improved symptoms or long-term clinical outcomes. |
| Ionescu and Frohman, 2006: GH pulsatility Hormone-sampling study in healthy men | Investigators examined GH secretion patterns following long-acting CJC-1295. | The study was not a sermorelin comparison or a trial of anti-aging outcomes. |
How are they related?
Both are discussed within growth hormone-releasing hormone research. Molecular modifications and duration of exposure are relevant differences, but those properties alone cannot establish which compound helps a patient.
What does DAC mean in CJC-1295 discussions?
DAC refers to the drug affinity complex associated with the long-acting molecule. The cited clinical work studied long-acting CJC-1295. A product advertised as CJC-1295 no DAC needs its own molecular identity and supporting evidence; the similar name is not enough to borrow the long-acting trial results.
What did the CJC-1295 studies measure?
They focused on endocrine responses in healthy adults. A measurable GH or IGF-1 response is not the same result as improved strength, sleep, symptoms or life expectancy. Those outcomes require their own studies.
What comparison can we actually make?
The evidence describes different research settings and a historical regulatory record. It does not directly test sermorelin against CJC-1295 for a shared clinical outcome. We therefore describe the evidence rather than assign a winner.
How to check a product or paper name
Record the exact peptide identity, terminal modifications, salt form and any conjugate named in the paper or report. Match those details before interpreting a half-life or a hormone response. A marketing abbreviation should be the start of that check, not its conclusion.
Common questions
Is CJC-1295 no DAC the same as the compound in the long-acting trial?
Do not assume so. The long-acting trial cannot establish the pharmacokinetics of a different molecular form simply because a listing uses CJC-1295 in its name.
Is sermorelin better than CJC-1295?
The selected evidence does not establish a head-to-head clinical ranking. The answer would require a defined population and outcome.
Does a longer half-life mean greater benefit?
No. Duration of exposure is a pharmacokinetic property; benefits and harms must be measured separately.
Continue your research
Educational information only. This page does not recommend a medicine, dose or injection protocol. Report a correction with its source.